An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood

被引:8
作者
Tsakalozou, Eleftheria [1 ]
Horn, Jamie [1 ]
Leggas, Mark [1 ]
机构
[1] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA
基金
美国国家卫生研究院;
关键词
AR-67; HPLC; validation; whole blood; MAMMALIAN TOPOISOMERASE-I; HUMAN SERUM-ALBUMIN; PHASE-I; ANTICANCER ACTIVITY; SOLID TUMORS; TOPOTECAN; IRINOTECAN; PHARMACOKINETICS; INHIBITION; GIMATECAN;
D O I
10.1002/bmc.1404
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin, DB-67) is a camptothecin analog currently in early stage clinical trials. The lactone moiety of camptothecins hydrolyzes readily in blood to yield the pharmacologically inactive carboxylate form. However the lactone form of third-generation lipophilic congeners, such as AR-67, is more stable, possibly due to partitioning into red cell membranes. This prompted us to develop a reverse-phase HPLC method with fluorescence detection (excitation 380 nm/emission 560 nm), which could quantitate the concentration of AR-67 lactone and carboxylate in whole blood. Samples were prepared by red cell lysis, protein precipitation with methanol and centrifugation to remove denatured materials. Recovery was estimated to be >85%. Analytes were eluted isocratically with 0.15 M ammonium acetate buff er containing 10 mM TBAP (pH 6.5) and acetonitrile (65: 35, v/v) on a Nova-Pak C-18 column (4 mm; 3.9 150 mm). The assay was linear in the ranges 0.5-300 and 2.5-300 ng/mL for carboxylate and lactone, respectively. Accuracy and precision were acceptable. AR-67 forms were stable in whole blood and in methanolic supernatants. This assay has been successfully applied to measure AR-67 concentrations in whole blood of patients enrolled in a phase I study. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:1045 / 1051
页数:7
相关论文
共 28 条
[21]   REDUCED ALBUMIN-BINDING PROMOTES THE STABILITY AND ACTIVITY OF TOPOTECAN IN HUMAN BLOOD [J].
MI, ZH ;
MALAK, H ;
BURKE, TG .
BIOCHEMISTRY, 1995, 34 (42) :13722-13728
[22]   Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods [J].
Oguma, T .
JOURNAL OF CHROMATOGRAPHY B, 2001, 764 (1-2) :49-58
[23]   OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT [J].
PECK, CC ;
BARR, WH ;
BENET, LZ ;
COLLINS, J ;
DESJARDINS, RE ;
FURST, DE ;
HARTER, JG ;
LEVY, G ;
LUDDEN, T ;
RODMAN, JH ;
SANATHANAN, L ;
SCHENTAG, JJ ;
SHAH, VP ;
SHEINER, LB ;
SKELLY, JP ;
STANSKI, DR ;
TEMPLE, RJ ;
VISWANATHAN, CT ;
WEISSINGER, J ;
YACOBI, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (06) :826-833
[24]  
Rothenberg ML, 1998, ONCOLOGY-NY, V12, P68
[25]   Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors [J].
Sessa, C. ;
Cresta, S. ;
Cerny, T. ;
Baselga, J. ;
Caremoli, E. Rota ;
Malossi, A. ;
Hess, D. ;
Trigo, J. ;
Zucchetti, M. ;
D'Incalci, M. ;
Zaniboni, A. ;
Capri, G. ;
Gatti, B. ;
Carminati, P. ;
Zanna, C. ;
Marsoni, S. ;
Gianni, L. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :561-568
[26]  
US FDA, 2001, GUID IND BIOAN METH
[27]  
van Riel JMGH, 2002, CLIN CANCER RES, V8, P405
[28]   Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors [J].
Zamboni, WC ;
Bowman, LC ;
Tan, M ;
Santana, VM ;
Houghton, PJ ;
Meyer, WH ;
Pratt, CB ;
Heideman, RL ;
Gajjar, AJ ;
Pappo, AS ;
Stewart, CF .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (06) :454-460